Bagsværd, Denmark, 22 July 2019 – On 7 May 2019, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 15 billion to be executed during a 12-month period beginning 1 February 2019.
Under the programme initiated 7 May 2019, Novo Nordisk will repurchase B shares for an amount up to DKK 2.7 billion in the period from 8 May 2019 to 7 August 2019.
Since the announcement as of 15 July 2019, the following transactions have been made under the programme:
Number of B shares | Average purchase price | Transaction value, DKK | |
Accumulated, last announcement | 5,788,400 | 1,909,190,965 | |
15 July 2019 | 135,000 | 317.33 | 42,839,778 |
16 July 2019 | 135,000 | 318.80 | 43,038,633 |
17 July 2019 | 135,000 | 321.53 | 43,407,138 |
18 July 2019 | 135,000 | 321.93 | 43,460,372 |
19 July 2019 | 135,000 | 318.54 | 43,002,719 |
Accumulated under the programme | 6,463,400 | 2,124,939,605 |
The details for each transaction made under the share repurchase programme are published on novonordisk.com.
With the transactions stated above, Novo Nordisk owns a total of 28,806,543 B shares of DKK 0.20, corresponding to 1.2% of the share capital, as treasury shares. The total amount of A and B shares in the company is 2,400,000,000 including treasury shares.
Novo Nordisk expects to repurchase B shares for an amount up to DKK 15 billion during a 12-month period beginning 1 February 2019. As of 19 July 2019, Novo Nordisk has since 1 February 2019 repurchased a total of 21,639,904 B shares at an average share price of DKK 326.24 per B share equal to a transaction value of DKK 7,059,893,206.
Further information
Media: | ||
Anne Margrethe Hauge | +45 4442 3450 | amhg@novonordisk.com |
Ken Inchausti (US) | +1 609 240 9429 | kiau@novonordisk.com |
Investors: | ||
Peter Hugreffe Ankersen | +45 3075 9085 | phak@novonordisk.com |
Valdemar Borum Svarrer | +45 3079 0301 | jvls@novonordisk.com |
Ann Søndermølle Rendbæk | +45 3075 2253 | arnd@novonordisk.com |
Kristoffer Due Berg (US) | +1 609 235 2989 | krdb@novonordisk.com |
Company announcement No 42 / 2019
Attachment